Evidence map›Paper›PMID 31214178›Full record

ArticleFrontiers in immunology2019

The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.

Donald T Weed, Serena Zilio, Isildinha M Reis, Zoukaa Sargi, Marianne Abouyared, Carmen R Gomez-Fernandez, Francisco J Civantos, Carla P Rodriguez, Paolo Serafini

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02544880 (PDE5 Inhibition Via Tadalafil), which is not on this map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02544880 phase1completednot on this map

PDE5 Inhibition Via Tadalafil (Cialis®) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial

TypeinterventionalSponsorDonald T. Weed, MD, FACSRan2016 to 2021Enrolled16ConditionsHead and Neck Squamous Cell Carcinoma, Head and Neck CancerArmsTadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 59 citations in OpenAlex.

  1. Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Neutrophil diversity and function in health and disease.Signal transduction and targeted therapy · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Donald T WeedDepartment of Otolaryngology, Miller School of Medicine, University of Miami, Miami, FL, United States.
Serena ZilioDepartment of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, United States.
Isildinha M ReisDepartment of Public Health Sciences and Sylvester Biostatistics and Bioinformatics Core Resource, Miller School of Medicine, University of Miami, Miami, FL, United States.
Zoukaa SargiDepartment of Otolaryngology, Miller School of Medicine, University of Miami, Miami, FL, United States.
Marianne AbouyaredDepartment of Otolaryngology, Miller School of Medicine, University of Miami, Miami, FL, United States.
Carmen R Gomez-FernandezDepartment of Pathology and Laboratory Medicine, Miller School of Medicine, University of Miami, Miami, FL, United States.
Francisco J CivantosDepartment of Otolaryngology, Miller School of Medicine, University of Miami, Miami, FL, United States.
Carla P RodriguezDepartment of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, United States.
Paolo SerafiniDepartment of Otolaryngology, Miller School of Medicine, University of Miami, Miami, FL, United States.
University of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid Derived suppressor cells (MDSCs) play a key role in the progression and recurrence of human malignancies and in restraining the efficacy of adjuvant therapies. We have previously shown that Tadalafil lowers MDSCs and regulatory T cells (Treg) in the blood and in the tumor, primes a tumor specific immune response, and increases the number of activated intratumoral CD8

Indexed as

Gene Expression Regulation, NeoplasticB7-H1 AntigenBiomarkersCancer VaccinesCombined Modality TherapyHumansImmunohistochemistryImmunomodulationKaplan-Meier EstimateMyeloid-Derived Suppressor CellsNeoplasm StagingSquamous Cell Carcinoma of Head and NeckTadalafilTreatment OutcomeB7-H1 AntigenBiomarkersCancer VaccinesCD274 protein, humanTadalafilimmune exclusionmucin 1 vaccinemyeloid derived suppressor cellsPDE5PDL1poly-ICLCrecurrent HNSCCtadalafil

Identifiers

PMID31214178
PMCPMC6554471
OpenAlexW2947889556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.